Centauri Therapeutics is an immunotherapy company focused on infectious diseases. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases. Centauri holds an exclusive worldwide license to exploit the Alphamer® immunotherapeutics platform within the field of infectious diseases.
Alphamers are modular molecules with three components.
A targeting moiety whose structure recognises and binds to a target of interest on the pathogen. This moiety may be a small molecule, a monoclonal antibody or peptide, for example.
A customisable, proprietary linker.
The immunological effector moiety which displays sugar epitopes, leading to the recruitment of pre-existing polyclonal antibody repertoire.
The Centauri Alphamer process
Alphamers operate by attracting the body’s own pre-existing polyclonal anti-glycan antibodies. Coating of the antibodies leads to an acute immune response including cytolytic events such as complement fixation.
For example, in Gram-negative bacteria:
Kary Mullis PhD
Science consistently produces a new crop of miraculous truths and dazzling devices every year.
Nobel Laureate (1944-2019)